In-vivo MRI of noradrenergic and dopaminergic nuclei predicts future cognition and Alzheimers disease progression

In 739 ADNI participants, lower baseline locus coeruleus (LC) MRI contrast predicts 84% higher five-year odds of MCI-to-AD progression.

• Why it matters: Noradrenergic and dopaminergic nuclei are implicated early in Alzheimer’s disease, but it is unclear whether in-vivo MRI measures can forecast later cognitive decline before symptoms worsen.
• What they did: The study derived LC and substantia nigra–ventral tegmental area (SN-VTA) MRI integrity metrics, linked them to post-mortem MRI-histology correspondence, and tested whether baseline contrast predicted cognition 10 years later.
• The result: LC and SN-VTA contrast forecast later cognitive and behavioral function, aligned with PET norepinephrine-transporter and dopamine-receptor maps, and their predictive effects were mediated by corresponding brain-wide atrophy patterns.

AI summary of the abstract · may contain errors · not medical advice · read the paper.